Literature DB >> 27074423

Irreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go.

L J Savic, J Chapiro, B Hamm, B Gebauer, F Collettini.   

Abstract

UNLABELLED: Irreversible electroporation (IRE) is the latest in the series of image-guided locoregional tumor ablation therapies. IRE is performed in a nearly non-thermal fashion that circumvents the "heat sink effect" and allows for IRE application in proximity to critical structures such as bile ducts or neurovascular bundles, where other techniques are unsuitable. IRE appears generally feasible and initial reported results for tumor ablation in the liver, pancreas and prostate are promising. Additionally, IRE demonstrates a favorable safety profile. However, site-specific complications include bile leaking or vein thrombosis and may be more severe after pancreatic IRE compared to liver or prostate ablation. There is limited clinical evidence in support of the use of IRE in the kidney. In contrast, pulmonary IRE has so far failed to demonstrate efficacy due to practicability limitations. Hence, this review will provide a state-of-the-art update on available clinical evidence of IRE regarding feasibility, safety and oncologic efficacy. The future role of IRE in the minimally invasive treatment of solid tumors will be discussed. KEY POINTS: • Preclinical findings of IRE have been successfully translated into clinical settings.• Non-thermal ablation is able to prevent the "heat sink effect" and collateral damage.• IRE should primarily be applied to tumors adjacent to sensitive structures (e. g. bile ducts).IRE efficacy appears promising in the liver, pancreas and prostate with tolerable morbidity.• In contrast, there are no evidential benefits of IRE in the lung parenchyma. Citation Format: • Savic LJ, Chapiro J, Hamm B et al. Irreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go. Fortschr Röntgenstr 2016; 188: 735 - 745. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2016        PMID: 27074423     DOI: 10.1055/s-0042-104203

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  15 in total

Review 1.  Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions.

Authors:  Meaghan S Dendy; Johannes M Ludwig; Stacey M Stein; Hyun S Kim
Journal:  Liver Cancer       Date:  2019-01-16       Impact factor: 11.740

2.  Preclinical and clinical evaluation of the liver tumor irreversible electroporation by magnetic resonance imaging.

Authors:  Matteo Figini; Xifu Wang; Tianchu Lyu; Zhanliang Su; Daniele Procissi; Vahid Yaghmai; Andrew C Larson; Zhuoli Zhang
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

3.  MRI-TRUS fusion for electrode positioning during irreversible electroporation for treatment of prostate cancer.

Authors:  Alexander D J Baur; Federico Collettini; Judith Enders; Andreas Maxeiner; Vera Schreiter; Carsten Stephan; Bernhard Gebauer; Bernd Hamm; Thomas Fischer
Journal:  Diagn Interv Radiol       Date:  2017 Jul-Aug       Impact factor: 2.630

4.  In vivo evaluation of bronchial injury of irreversible electroporation in a porcine lung ablation model by using laboratory, pathological, and CT findings.

Authors:  Jun-Hui Sun; Tong-Yin Zhu; Xin-Hua Chen; Chun-Hui Nie; Zhi-Gang Ren; Guan-Hui Zhou; Tan-Yang Zhou; Sheng-Yong Yin; Zhi-Yi Peng; Li-Ming Wu; Xiong-Xin Zhang; Wei-Lin Wang; Shu-Sen Zheng
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

Review 5.  Ablation of Intrahepatic Cholangiocarcinoma.

Authors:  Jennifer Sweeney; Nainesh Parikh; Ghassan El-Haddad; Bela Kis
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

6.  Percutaneous Ablation of Hepatic Tumors at the Hepatocaval Confluence Using Irreversible Electroporation: A Preliminary Study.

Authors:  Tiankuan Li; Wei Huang; Zhiyuan Wu; Yong Wang; Qingbing Wang; Ziyin Wang; Qin Liu; Jingjing Liu; Shenjie Wang; Xiaoyi Ding; Zhongmin Wang
Journal:  Curr Oncol       Date:  2022-05-31       Impact factor: 3.109

7.  A Comparative Study of Ablation Boundary Sharpness After Percutaneous Radiofrequency, Cryo-, Microwave, and Irreversible Electroporation Ablation in Normal Swine Liver and Kidneys.

Authors:  Francois H Cornelis; Jeremy C Durack; Simon Y Kimm; Thomas Wimmer; Jonathan A Coleman; Stephen B Solomon; Govindarajan Srimathveeravalli
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-17       Impact factor: 2.740

Review 8.  Ablation of hepatic malignant tumors with irreversible electroporation: A systematic review and meta-analysis of outcomes.

Authors:  Guo Tian; Qiyu Zhao; Fen Chen; Tian'an Jiang; Weilin Wang
Journal:  Oncotarget       Date:  2017-01-24

9.  Synergistic combinations of short high-voltage pulses and long low-voltage pulses enhance irreversible electroporation efficacy.

Authors:  Chenguo Yao; Yanpeng Lv; Yajun Zhao; Shoulong Dong; Hongmei Liu; Jianhao Ma
Journal:  Sci Rep       Date:  2017-11-09       Impact factor: 4.379

Review 10.  Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Bela Kis; Ghassan El-Haddad; Rahul A Sheth; Nainesh S Parikh; Suvranu Ganguli; Paul B Shyn; Junsung Choi; Karen T Brown
Journal:  Cancer Control       Date:  2017 Jul-Sep       Impact factor: 3.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.